Payment overview · 2025
General Payments
$544.92
29 reported records · 13 companies
Healthcare provider profile · identity verified
James Daniel Mcavoy, MD
Allopathic & Osteopathic Physicians|Family Medicine · ELBERTON, GA · NPI 1215917901
Verified facts
What the public records show
CMS Open Payments records show James Daniel Mcavoy, MD received $544.92 in general payments during 2025 across 29 reported records.
Novo Nordisk Inc accounted for 15.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic, Rybelsus, Shingrix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 316 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 197 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 197 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 154 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 250 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 917 claims for Eliquis by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 129 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $86.64 | 15.9% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $81.29 | 14.9% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $46.66 | 8.6% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $45.50 | 8.3% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $45.09 | 8.3% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $39.69 | 7.3% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $38.19 | 7.0% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $35.34 | 6.5% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $33.18 | 6.1% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $32.12 | 5.9% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $26.34 | 4.8% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.71 | 3.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.17 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $544.92 | 29 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $59.57 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $54.25 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $45.50 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $45.50 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $45.09 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $43.37 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $39.69 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $38.19 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $35.34 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $35.34 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $32.84 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $32.84 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $32.39 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $32.12 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $26.34 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $21.72 | 1 | 2025 |
Source payment records
|
|||||
| PENBRAYA Normalized: penbraya |
Biological | PFIZER INC. | $21.72 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $21.72 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $18.71 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $16.89 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.29 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.17 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.22 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $13.82 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 316 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 197 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 51 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 250 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 30 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
77 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
55 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
316 | 29 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
57 | 12 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
197 | 25 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
30 | 27 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
197 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
51 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
154 | 18 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
250 | 35 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
18 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
917 | 90 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
129 | 28 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1700 | 240 |
| Amlodipine Besylate | Amlodipine Besylate | 1589 | 312 |
| Furosemide | Furosemide | 1495 | 201 |
| Potassium Chloride | Potassium Chloride | 1357 | 173 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1221 | 181 |
| Eliquis | Apixaban | 917 | 90 |
| Omeprazole | Omeprazole | 883 | 153 |
| Losartan Potassium | Losartan Potassium | 881 | 166 |
| Trazodone Hcl | Trazodone Hcl | 866 | 101 |
| Lisinopril | Lisinopril | 855 | 135 |
| Metoprolol Succinate | Metoprolol Succinate | 851 | 145 |
| Gabapentin | Gabapentin | 848 | 147 |
| Famotidine | Famotidine | 698 | 125 |
| Metformin Hcl | Metformin Hcl | 671 | 120 |
| Mirtazapine | Mirtazapine | 650 | 70 |
| Divalproex Sodium | Divalproex Sodium | 609 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 578 | 63 |
| Metoprolol Tartrate | Metoprolol Tartrate | 559 | 85 |
| Hydrochlorothiazide | Hydrochlorothiazide | 538 | 140 |
| Pravastatin Sodium | Pravastatin Sodium | 527 | 94 |
| Quetiapine Fumarate | Quetiapine Fumarate | 525 | 45 |
| Escitalopram Oxalate | Escitalopram Oxalate | 520 | 77 |
| Tramadol Hcl | Tramadol Hcl | 512 | 112 |
| Tamsulosin Hcl | Tamsulosin Hcl | 487 | 76 |
| Fluoxetine Hcl | Fluoxetine Hcl | 472 | 37 |
| Fluticasone Propionate | Fluticasone Propionate | 464 | 143 |
| Meloxicam | Meloxicam | 459 | 96 |
| Donepezil Hcl | Donepezil Hcl | 451 | 39 |
| Duloxetine Hcl | Duloxetine Hcl | 433 | 38 |
| Hydralazine Hcl | Hydralazine Hcl | 383 | 70 |
| Carvedilol | Carvedilol | 377 | 70 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 367 | 35 |
| Sertraline Hcl | Sertraline Hcl | 362 | 52 |
| Topiramate | Topiramate | 353 | 11 |
| Simvastatin | Simvastatin | 343 | 75 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 335 | 65 |
| Farxiga | Dapagliflozin Propanediol | 316 | 29 |
| Baclofen | Baclofen | 312 | 31 |
| Spironolactone | Spironolactone | 310 | 35 |
| Clopidogrel | Clopidogrel Bisulfate | 307 | 52 |
| Buspirone Hcl | Buspirone Hcl | 291 | 27 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 288 | 57 |
| Memantine Hcl | Memantine Hcl | 287 | 38 |
| Sucralfate | Sucralfate | 287 | 33 |
| Lorazepam | Lorazepam | 271 | 53 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 264 | 86 |
| Ozempic | Semaglutide | 250 | 35 |
| Amitriptyline Hcl | Amitriptyline Hcl | 248 | 22 |
| Montelukast Sodium | Montelukast Sodium | 248 | 43 |
| Doxycycline Hyclate | Doxycycline Hyclate | 243 | 211 |
| Allopurinol | Allopurinol | 242 | 45 |
| Zolpidem Tartrate | Zolpidem Tartrate | 230 | 40 |
| Xarelto | Rivaroxaban | 204 | 22 |
| Glipizide | Glipizide | 202 | 56 |
| Jardiance | Empagliflozin | 197 | 25 |
| Clonazepam | Clonazepam | 194 | 29 |
| Glipizide Er | Glipizide | 188 | 42 |
| Tizanidine Hcl | Tizanidine Hcl | 183 | 39 |
| Doxazosin Mesylate | Doxazosin Mesylate | 182 | 27 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 179 | 48 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 176 | 43 |
| Aripiprazole | Aripiprazole | 175 | suppressed |
| Levetiracetam | Levetiracetam | 172 | 19 |
| Lamotrigine | Lamotrigine | 171 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 165 | 19 |
| Divalproex Sodium Er | Divalproex Sodium | 161 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 158 | 30 |
| Metformin Hcl Er | Metformin Hcl | 158 | 31 |
| Trulicity | Dulaglutide | 154 | 18 |
| Alprazolam | Alprazolam | 149 | 35 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 146 | 28 |
| Finasteride | Finasteride | 141 | 30 |
| Januvia | Sitagliptin Phosphate | 141 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 136 | 29 |
| Prednisone | Prednisone | 135 | 94 |
| Alendronate Sodium | Alendronate Sodium | 134 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 134 | 27 |
| Ondansetron Hcl | Ondansetron Hcl | 134 | 44 |
| Atenolol | Atenolol | 133 | 36 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 129 | 28 |
| Oxybutynin Chloride | Oxybutynin Chloride | 128 | 22 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 127 | 63 |
| Citalopram Hbr | Citalopram Hydrobromide | 120 | 26 |
| Nifedipine Er | Nifedipine | 118 | 21 |
| Pregabalin | Pregabalin | 117 | 24 |
| Benazepril Hcl | Benazepril Hcl | 116 | 21 |
| Ezetimibe | Ezetimibe | 113 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 113 | 19 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 110 | 13 |
| Torsemide | Torsemide | 110 | suppressed |
| Ibuprofen | Ibuprofen | 108 | 27 |
| Clonidine Hcl | Clonidine Hcl | 107 | 25 |
| Tresiba Flextouch U-100 | Insulin Degludec | 105 | 15 |
| Midodrine Hcl | Midodrine Hcl | 104 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 102 | 33 |
| Cephalexin | Cephalexin | 97 | 79 |
| Lovastatin | Lovastatin | 97 | 23 |
| Colchicine | Colchicine | 95 | 31 |
| Paroxetine Hcl | Paroxetine Hcl | 87 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 85 | 34 |
| Lactulose | Lactulose | 85 | 18 |
| Calcitriol | Calcitriol | 80 | suppressed |
| Estradiol | Estradiol | 79 | 25 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 78 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 77 | suppressed |
| Azithromycin | Azithromycin | 77 | 69 |
| Creon | Lipase/Protease/Amylase | 77 | suppressed |
| Olanzapine | Olanzapine | 77 | suppressed |
| Primidone | Primidone | 76 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 75 | 66 |
| Oxcarbazepine | Oxcarbazepine | 74 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 74 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 69 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 68 | 16 |
| Risperidone | Risperidone | 66 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 65 | suppressed |
| Bupropion Xl | Bupropion Hcl | 65 | 13 |
| Ondansetron Odt | Ondansetron | 63 | 31 |
| Oxycodone Hcl | Oxycodone Hcl | 62 | 15 |
| Propranolol Hcl | Propranolol Hcl | 62 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 61 | 29 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 61 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 61 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 59 | 49 |
| Klor-Con M20 | Potassium Chloride | 58 | 23 |
| Fluconazole | Fluconazole | 57 | 33 |
| Symbicort | Budesonide/Formoterol Fumarate | 57 | 12 |
| Promethazine Hcl | Promethazine Hcl | 56 | 19 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 56 | 17 |
| Synthroid | Levothyroxine Sodium | 55 | 13 |
| Trintellix | Vortioxetine Hydrobromide | 55 | suppressed |
| Probenecid | Probenecid | 52 | suppressed |
| Mounjaro | Tirzepatide | 51 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 51 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 50 | suppressed |
| Methylprednisolone | Methylprednisolone | 49 | 47 |
| Valsartan | Valsartan | 48 | 14 |
| Latanoprost | Latanoprost | 47 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 45 | 37 |
| Theophylline Er | Theophylline Anhydrous | 45 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 44 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 44 | suppressed |
| Nitroglycerin | Nitroglycerin | 44 | 20 |
| Temazepam | Temazepam | 44 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 42 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 42 | suppressed |
| Diazepam | Diazepam | 42 | 13 |
| Rybelsus | Semaglutide | 41 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 41 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 38 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 38 | 38 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 38 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 38 | suppressed |
| Acyclovir | Acyclovir | 37 | 12 |
| Cholestyramine | Cholestyramine (With Sugar) | 37 | 22 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 37 | 29 |
| Venlafaxine Hcl | Venlafaxine Hcl | 37 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 36 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 36 | 11 |
| Celecoxib | Celecoxib | 35 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 35 | suppressed |
| Levetiracetam Er | Levetiracetam | 34 | suppressed |
| Novolog Flexpen | Insulin Aspart | 34 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 33 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 33 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 33 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 33 | suppressed |
| Novolog | Insulin Aspart | 33 | suppressed |
| Verapamil Er | Verapamil Hcl | 33 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 32 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 32 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 31 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 31 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 30 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 30 | suppressed |
| Methimazole | Methimazole | 30 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 30 | 27 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 29 | suppressed |
| Mupirocin | Mupirocin | 29 | 18 |
| Levemir | Insulin Detemir | 28 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 27 | suppressed |
| Hydrocortisone | Hydrocortisone | 27 | 14 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 27 | 11 |
| Chlorthalidone | Chlorthalidone | 26 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 26 | suppressed |
| Klor-Con M10 | Potassium Chloride | 26 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 25 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 25 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 24 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 24 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 24 | 14 |
| Irbesartan | Irbesartan | 24 | suppressed |
| Movantik | Naloxegol Oxalate | 24 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 24 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Clotrimazole | Clotrimazole | 23 | 17 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 23 | 18 |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 23 | suppressed |
| Myrbetriq | Mirabegron | 23 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Naproxen | Naproxen | 23 | suppressed |
| Risperdal Consta | Risperidone Microspheres | 23 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 22 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 22 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 22 | suppressed |
| Belsomra | Suvorexant | 21 | suppressed |
| Levofloxacin | Levofloxacin | 21 | 20 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 20 | suppressed |
| Entresto | Sacubitril/Valsartan | 20 | suppressed |
| Indapamide | Indapamide | 20 | suppressed |
| Trimethoprim | Trimethoprim | 20 | suppressed |
| Carbamazepine | Carbamazepine | 19 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 19 | suppressed |
| Ibu | Ibuprofen | 19 | suppressed |
| Nystatin | Nystatin | 19 | 14 |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 18 | 18 |
| Cefdinir | Cefdinir | 18 | 17 |
| Clobetasol Propionate | Clobetasol Propionate | 18 | suppressed |
| Constulose | Lactulose | 18 | suppressed |
| Methotrexate | Methotrexate Sodium | 18 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 17 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 17 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 17 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 17 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 17 | suppressed |
| Carisoprodol | Carisoprodol | 16 | suppressed |
| Enulose | Lactulose | 16 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 16 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 16 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | 14 |
| Timolol Maleate | Timolol Maleate | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Humalog | Insulin Lispro | 14 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 14 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Budesonide | Budesonide | 13 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 13 | 11 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 13 | suppressed |
| Alogliptin | Alogliptin Benzoate | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Clobazam | Clobazam | 12 | suppressed |
| Enbrel Sureclick | Etanercept | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Insulin Lispro | Insulin Lispro | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Trulance | Plecanatide | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Veo Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 11 | suppressed |
| Dilantin | Phenytoin | 11 | suppressed |
| Eplerenone | Eplerenone | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 11 | suppressed |
| Xifaxan | Rifaximin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $544.92 · 29 records | Novo Nordisk Inc | AIRSUPRA, COMIRNATY, Dexcom G6 Transmitter, FARXIGA, GVOKE HYPOPEN, JARDIANCE, Korlym, LEQVIO, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PENBRAYA, PREVNAR 20, QULIPTA, REPATHA, Rybelsus, SHINGRIX, TZIELD, UBRELVY, VRAYLAR, Wegovy, ZAVZPRET, ZEPBOUND | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error